La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Takara Bio Gestione

Gestione criteri di controllo 2/4

Takara Bio's Il CEO è Koichi Nakao, nominato in May2009, ha un mandato di 15.25 anni. possiede direttamente 0.061% delle azioni della società, per un valore di ¥ 76.94M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 5.7 anni.

Informazioni chiave

Koichi Nakao

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	15.3yrs
Proprietà del CEO	0.06%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Koichi Nakao (62 yo)

15.3yrs

Mandato

Mr. Koichi Nakao was Director & President of Takara Bio Inc. from May 2009 to April 2020. Mr. Nakao was Director of Takara Bio Inc. from April 2002 to May 2009. He serves as Senior Managing Executive Offic...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Koichi Nakao	CEO, President & Representative Director	15.3yrs	Nessun dato	0.061% ¥ 74.1m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	2.7yrs	Nessun dato	0.014% ¥ 17.1m
Takuya Kakemi	Executive Officer	no data	Nessun dato	Nessun dato
Akira Kodera	Managing Executive Officer & Head of Sales Division	1.7yrs	Nessun dato	Nessun dato
Noritaka Nishiwaki	Executive Officer	no data	Nessun dato	Nessun dato
Tsuyoshi Miyamura	Senior Managing Director & Director	10.3yrs	Nessun dato	0.011% ¥ 13.6m
Junichi Mineno	VP, Executive Officer & Director	2.7yrs	Nessun dato	0.012% ¥ 14.5m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	7.3yrs	Nessun dato	0.0040% ¥ 4.8m
Andrew Farmer	Head of Research and Development	no data	Nessun dato	Nessun dato
Kyoko Nakajima	Managing Executive Officer & Head of SCM Division	1.7yrs	Nessun dato	Nessun dato
Ikuei Nukaya	Managing Executive Officer & Head of Quality Control Headquarters	less than a year	Nessun dato	Nessun dato

2.7yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di 4974 è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Koichi Nakao	CEO, President & Representative Director	22.4yrs	Nessun dato	0.061% ¥ 74.1m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	3.3yrs	Nessun dato	0.014% ¥ 17.1m
Tsuyoshi Miyamura	Senior Managing Director & Director	6.3yrs	Nessun dato	0.011% ¥ 13.6m
Junichi Mineno	VP, Executive Officer & Director	10.3yrs	Nessun dato	0.012% ¥ 14.5m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	1.7yrs	Nessun dato	0.0040% ¥ 4.8m
Mutsumi Kimura	Director	2.3yrs	Nessun dato	0.043% ¥ 51.8m
Kazuko Kimura	Independent External Director	5.3yrs	Nessun dato	Nessun dato
Nobuko Kawashima	Independent External Director	8.3yrs	Nessun dato	Nessun dato
Yasuo Himeiwa	Independent Outside Audit & Supervisory Board Member	no data	Nessun dato	Nessun dato
Kunihiko Kamada	Independent Outside Audit & Supervisory Board Member	no data	Nessun dato	Nessun dato
Masaaki Makikawa	Independent Outside Audit & Supervisory Board Member	no data	Nessun dato	Nessun dato
Noriomi Matsumura	Independent External Director	4.3yrs	Nessun dato	Nessun dato

5.3yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4974 sono considerati esperti (durata media dell'incarico 5.7 anni).

Takara Bio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Less than half of directors are independent

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Takara Bio Inc. to Report Q2, 2025 Results on Nov 08, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 17%

Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Consensus EPS estimates fall by 30%

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024

Consensus EPS estimates fall by 56%

Price target decreased by 17% to JP¥1,600

Upcoming dividend of JP¥17.00 per share

Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD)

Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 29%, revenue downgraded

Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 15%

Price target decreased by 17% to JP¥1,933

Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023

Takara Bio Inc. to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥42.00 per share at 2.3% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023

Price target decreased to JP¥2,250

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥2,400

Takara Bio Inc. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥2,515

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Takara Bio Inc. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥30.00 per share

Consensus revenue estimates increase by 16%

Price target decreased to JP¥2,742

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥2,792

Price target decreased to JP¥3,012

Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021)

Consensus EPS estimates increase to JP¥91.00

First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021)

Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Takara Bio Inc. to Report Fiscal Year 2021 Results on May 13, 2021

Analysts increase EPS estimates to JP¥53.65

Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020)

New 90-day high: JP¥3,045

New 90-day low: JP¥2,752

Takara Bio Inc. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: JP¥3,020

Takara Bio Inc. to Report Q2, 2021 Results on Nov 10, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente